NASDAQ$ZIMV

ZimVie Inc · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

ZimVie's third-party net sales reached $233.4 million, with a net loss of ($8.7) million and a diluted EPS of ($0.33).

ZimVie reported a decrease in third-party net sales by (11.5%) on a reported basis and (8.3%) on a constant currency basis compared to Q2 2021. The company's net loss increased to ($8.7) million, and diluted EPS was ($0.33). However, cash and cash equivalents increased to $130.1 million.

  • Third-party net sales were $233.4 million, a decrease of (11.5%) year-over-year.
  • Net loss was ($8.7) million, with a net loss margin of (3.7%).
  • Diluted EPS was ($0.33), and adjusted diluted EPS was $0.67.
  • Cash and cash equivalents totaled $130.1 million, up from $104.3 million at the end of Q1 2022.

Headline financials

Total Revenue

$235M

Previous: $266M-11.7%
EPS (adj)

$0.67

Previous: -$0.19+452.6%
Adjusted EBITDA

$31.3M

Previous: $38.1M-17.9%
Adjusted EBITDA Margin

13.4%

Previous: 14.5%-7.6%
Net Income

-$8.71M

Previous: -$4.74M-83.8%
Operating Income

-$21.5M

Previous: -$5.22M-312.4%
Gross Profit

$153M

Previous: $178M-14.0%
Cash & Equivalents

$130M

No prior period
Total Assets

$1.73B

No prior period
Stock-Based Comp

$6.22M

Previous: $1.92M+223.6%

Revenue & EPS history

ZimVie · Revenue · Quarterly

$235M

Q2 2022-11.7%vs Q2 2021
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Forward guidance

ZimVie revised its full-year 2022 net sales guidance to $915 to $930 million and adjusted EPS guidance from $2.10-$2.30 to $1.80-$2.00, while reaffirming adjusted EBITDA margin guidance of flat to 50bps improvement from the prior year.

Tailwinds

  • Reaffirming adjusted EBITDA margin guidance of flat to 50bps improvement from prior year margin of 13.1%.
  • Expect dental business to deliver near the lower end of prior mid to high single digit growth in constant currency

Headwinds

  • Revised net sales guidance to $915 to $930 million versus prior guidance of $1.0 billion due to greater than anticipated foreign exchange headwinds.
  • Expect spine business to decline in the low double digits in constant currency.
  • Revised adjusted EPS guidance from a range of $2.10 to $2.30 to $1.80 to $2.00 due primarily to lower sales.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

-1.7%

Avg return

Earnings day

-3.4%

Avg return

5 days after

-5.3%

Avg return

30 days after

44%

8 / 18 earnings

Positive

+24.0%

Q1 2023

Best reaction

-49.0%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025-0.4%-0.1%+0.1%
Q1 2025-4.4%-4.8%+2.2%
Q4 2024-1.7%+3.1%-11.9%
Q3 2024+0.6%+5.5%+6.2%
Q2 2024-18.2%-19.0%-17.9%
Q1 2024+5.7%+4.8%+0.8%
Q4 2023-14.4%-13.4%-16.9%
Q3 2023+5.4%
Q2 2023-6.0%
Q1 2023+24.0%
Q4 2022-49.0%
Q3 2021+20.0%
Q3 2022+20.0%
Q2 2021-8.2%
Q2 2022-8.2%
Q1 2021-6.5%
Q4 2021+5.1%
Q4 2020+5.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro